Cargando…
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic disea...
Autores principales: | de Galiza Barbosa, Felipe, Queiroz, Marcelo Araujo, Nunes, Rafael Fernandes, Costa, Larissa Bastos, Zaniboni, Elaine Caroline, Marin, José Flavio Gomes, Cerri, Giovanni Guido, Buchpiguel, Carlos Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071711/ https://www.ncbi.nlm.nih.gov/pubmed/32169115 http://dx.doi.org/10.1186/s40644-020-00300-7 |
Ejemplares similares
-
Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018) -
PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023) -
PET/CT in the evaluation of pulmonary solitary nodule
por: Barbosa, Felipe de Galiza
Publicado: (2016) -
Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT
por: Queiroz, Marcelo A., et al.
Publicado: (2015) -
Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT
por: Herrmann, Ken, et al.
Publicado: (2015)